Results 111 to 120 of about 104,289 (264)

Intestinal microbiome alterations in pediatric epilepsy: Implications for seizures and therapeutic approaches

Epilepsia Open, EarlyView.
Abstract The intestinal microbiome plays a pivotal role in maintaining host health through its involvement in gastrointestinal, immune, and central nervous system (CNS) functions. Recent evidence underscores the bidirectional communication between the microbiota, the gut, and the brain and the impact of this axis on neurological diseases, including ...
Teresa Ravizza, Greta Volpedo, Antonella Riva, Pasquale Striano, Annamaria Vezzani   +4 more
wiley   +1 more source

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

Screening and identification of novel peptides stimulating GLP‐1 secretion from plant proteins after simulated gastrointestinal digestion

Food Biomacromolecules, EarlyView.
Effects of digestive products of quinoa, oat, barley, and mungbean proteins on GLP‐1 secretion are investigated using STC‐1 cell and animal experiments, and novel GLP‐1 secretion‐stimulating peptides are successfully identified by column chromatography and LC–MS/MS.
Hongdong Song, Shaoxia Ren, Qiuyun Fu, Lei Xue, Kai Huang, Hongwei Cao, Zetang Zhang, Junhu Li, Xiao Guan   +8 more
wiley   +1 more source

Case Report: Large Cell Neuroendocrine Carcinoma of the Palatine Tonsil in a 76‐Year‐Old Patient

Head &Neck, EarlyView.
ABSTRACT Background Large cell neuroendocrine carcinoma (LCNEC) of the palatine tonsil is an extremely rare malignancy characterized by an aggressive clinical course and poor prognosis. Its nonspecific presentation often delays diagnosis. Methods We present the case of a 76‐year‐old female patient admitted to the Emergency Department with throat ...
Agnieszka Bugaj, Natalia Zagozda, Piotr Nogal, Gabriela Miczuga, Bartosz Czech, Jacek Banaszewski   +5 more
wiley   +1 more source

Treatment Patterns and Survival Outcomes of Head and Neck Merkel Cell Carcinoma: An Age‐Stratified Analysis

Head &Neck, EarlyView.
ABSTRACT Background H&N Merkel cell carcinoma (MCC) mainly affects elderly patients, yet age‐stratified treatment patterns and outcomes data are scarce. Methods We analyzed 88 consecutive H&N MCC patients (2000–2022) by age (< 75 vs. ≥ 75 years). OS was estimated by Kaplan–Meier analysis and MCC‐specific death with competing‐risks methods (cause ...
Igor Vainer, Lior Strinkovsky, Eyal Fenig, Gideon Bachar   +3 more
wiley   +1 more source

Pretreatment Cachexia Index Is Associated With Severe Treatment Toxicity and Overall Survival in HPV‐Negative Head and Neck Squamous Cell Carcinoma

Head &Neck, EarlyView.
ABSTRACT Introduction Cancer cachexia is characterized by skeletal muscle loss, poor nutrition, and systemic inflammation and is common in head and neck cancer. We evaluated whether the Cachexia Index (CXI) predicts treatment toxicity and survival in HPV‐negative HNSCC.
Gianluca Savoia, Michael P. Hier, Nader Sadeghi, Alex Mlynarek, Keith Richardson, Sabrina Daniela Silva Wurzba, Christina Tsien, George Shenouda, Khalil Sultanem, Nathaniel Bouganim, Khashayar Esfahani, Marco A. Mascarella   +11 more
wiley   +1 more source

Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors. [PDF]

J Clin Transl Endocrinol
Shahid M, Koch CA.
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Genomic characterization of aggressiveness in pituitary neuroendocrine tumors. [PDF]

Neuro Oncol
Benanteur N, Villa C, Bioletto F, Birtolo MF, De Murat D, Masliah-Planchon J, Gravrand V, Lebib I, Benkhellat M, Boezennec R, Allassonnière S, Letourneur F, Martin Y, Bonnet Serrano F, Jacob J, Calugaru V, Barat M, Dohan A, Arrondeau J, Huillard O, Raffin-Sanson ML, Emile JF, Raverot G, Libé R, Guignat L, Garcia C, Groussin L, Bertagna X, Gaillard S, Bertherat J, Jouinot A, Baussart B, Assié G.   +32 more
europepmc   +1 more source